Tag: ADC Bio
Sterling Pharma Solutions Acquires ADC Biotechnology
Global contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has announced the acquisition of ADC Biotechnology, a UK-based bioconjugation development services business specializing...
WHP Completes a New State of the Art Cleanroom for ADC...
The production of novel antibody-drug conjugates at ADC Biotechnology’s North Wales, United Kingdom, manufacturing plant has been boosted with the completion of a new...
Investing for the Future: Unlocking Advanced ADC Manufacturing Innovation
UPDATE: This event has been postponed until Fall 2019.
Investment in ADCs (antibody-drug conjugates) has surged due to some very compelling market trends that include: ...
PEGS 2019: Using Economic Modelling In the ADC Manufacturing Supply Chain
Antibody-drug conjugates have become a strong and promising strategy for the treatment of cancer, and, potentially emerging in therapeutic areas outside oncology and hematology.
Today,...
Downstream Bioconjugation Model May Reduce Overall ADC Development Cost
A 'downstream bioconjugation' method may present a new model in antibody-drug conjugate development and manufacturing. In contrast to the existing approaches – which undertake...
Poor Aggregation: Failing ADC Targets, Long Delays in Development and Wasted...
During all stages of development, including expression, refolding, downstream processing, formulation, sterilization, and storage, biotherapeutic proteins are subjected to aggregation and degradation. In the...
ADC Biotechnology Invests in New Bioconjugation Facility in North Wales, United...
UK-based ADC Biotechnology has secured investment for the construction of an $11 million* bioconjugation facility at its new site in Deeside, North Wales, UK.
The...
